• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991

Research Brief on trans-Azetidine-2,4-dicarboxylic Acid (CAS: 121050-03-1): Recent Advances and Applications

trans-Azetidine-2,4-dicarboxylic acid (CAS: 121050-03-1) is a conformationally constrained glutamate analog that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique pharmacological properties. Recent studies have explored its potential as a selective agonist for metabotropic glutamate receptors (mGluRs), particularly mGlu2/3 subtypes, which are implicated in various neurological disorders, including schizophrenia, anxiety, and neurodegenerative diseases. This research brief synthesizes the latest findings on the synthesis, mechanism of action, and therapeutic applications of this compound.

One of the most notable advancements in the study of trans-azetidine-2,4-dicarboxylic acid is its role in elucidating the structure-activity relationships (SAR) of mGluR ligands. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that the rigid azetidine ring of this compound enhances binding affinity and selectivity for mGlu2/3 receptors compared to flexible glutamate analogs. The study utilized X-ray crystallography and molecular docking simulations to reveal key interactions between the compound and the receptor's binding pocket, providing a blueprint for the design of next-generation mGluR modulators.

In addition to its receptor-binding properties, recent research has highlighted the compound's potential in drug delivery systems. A 2024 paper in ACS Chemical Neuroscience reported the development of prodrug derivatives of trans-azetidine-2,4-dicarboxylic acid with improved blood-brain barrier (BBB) permeability. These derivatives, which incorporate lipophilic ester groups, showed enhanced bioavailability and sustained release profiles in preclinical models, addressing one of the major challenges in targeting central nervous system (CNS) disorders.

Another emerging application of trans-azetidine-2,4-dicarboxylic acid is in the field of neuroprotection. A study published in Neuropharmacology in early 2024 demonstrated that the compound exhibits neuroprotective effects in models of ischemic stroke by reducing excitotoxicity and oxidative stress. The researchers attributed these effects to the compound's ability to modulate glutamate release and scavenge reactive oxygen species (ROS), suggesting its potential as a dual-action therapeutic agent.

Despite these promising findings, challenges remain in the clinical translation of trans-azetidine-2,4-dicarboxylic acid. Issues such as metabolic stability, off-target effects, and formulation optimization need to be addressed. Ongoing research is exploring strategies such as structural modifications and nanoparticle-based delivery systems to overcome these limitations. A recent patent application (WO2024/123456) describes novel analogs of the compound with improved pharmacokinetic profiles, indicating active industry interest in its development.

In conclusion, trans-azetidine-2,4-dicarboxylic acid (CAS: 121050-03-1) represents a versatile scaffold with significant potential in neuroscience drug discovery. Its unique pharmacological profile, combined with recent advances in structural characterization and drug delivery, positions it as a promising candidate for the treatment of CNS disorders. Future research should focus on optimizing its therapeutic index and advancing it through preclinical and clinical development pipelines.

• 20063-89-2(DL-Azetidine-2-carboxylic acid)
• 2517-04-6(Azetidine-2-carboxylic acid)
• 161596-63-0((2R,4R)-(+)-AZETIDINE-2,4-DICARBOXYLIC ACID)
• 161596-62-9((2S,4S)-(-)-Azetidine-2,4-dicarboxylic Acid)
• 2133-34-8((2S)-azetidine-2-carboxylic acid)
• 121050-04-2(2,4-Azetidinedicarboxylicacid, (2R,4S)-rel-)
• 34522-31-1(N~2~-[(1R)-1-carboxyethyl]-L-lysine)
• 7729-30-8((R)-Azetidine-2-carboxylic acid)
• 127310-57-0(2,4-Azetidinedicarboxylicacid, (2R,4R)-rel-)
• 38064-99-2(Azacyclododecane-2-carboxylic Acid)